STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #156 by analyst upside · 2026-08-12
VVOS
Vivos Therapeutics, Inc.
Healthcare · Market Cap $4M · P/E 0x
ANALYST PRICE TARGET
+572.6%
implied upside to consensus target
Current Price $0.31
Consensus Target $2.12
Bull Target $3.1
Bear Target $0.75
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
1
Sell
0
52-Week Low $0.29
52-Week High $5.12
YTD Return -87.6%
FUNDAMENTALS
Market Cap $4M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.14
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $20M
Profit Margin -127.7%
52-WEEK RANGE
52-Week Low $0.29
52-Week High $5.12
Current Price $0.31
Bear Target $0.75
Bull Target $3.1
● Now $0.31 ● Target $2.12
TRADING DATA
Avg Volume 2.4M
YTD Return -87.6%
Analyst Count 3
Consensus Buy
Upside to Target +572.6%
Last Updated 2026-08-12

ANALYST SUMMARY

Vivos Therapeutics, Inc. (VVOS) is currently trading at $0.31 with a Wall Street consensus price target of $2.12, implying potential upside of 572.6% over the next 12 months. 3 analysts currently cover VVOS, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $3.1, while the most cautious has a target of $0.75.

VVOS operates in the Healthcare sector with a market capitalisation of $4M. The stock is down 87.6% year-to-date and is currently trading near the lower end of its 52-week range of $0.29 – $5.12.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for VVOS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Ascendiant Capital - Reiterated
Buy → Buy 2026-06-04 Building track record
Ascendiant Capital - Reiterated
Buy → Buy 2026-04-22 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-04-17 31% win rate (48 calls)
Ascendiant Capital - Reiterated
Buy → Buy 2025-12-03 Building track record
HC Wainwright & Co. ● Initiated
Buy 2025-11-17 31% win rate (48 calls)
Ascendiant Capital - Reiterated
Buy → Buy 2025-09-09 Building track record
Ascendiant Capital - Reiterated
Buy → Buy 2025-04-15 Building track record
Ascendiant Capital reit
Buy → Buy 2024-11-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
25
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →